D-dimer to Select Patients With a First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months (DODS)
This study is ongoing, but not recruiting participants.
Sponsor:
McMaster University
Collaborator:
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
McMaster University
ClinicalTrials.gov Identifier:
NCT00720915
First received: July 21, 2008
Last updated: April 20, 2012
Last verified: April 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine if the risk of recurrent venous thromboembolism (VTE) after stopping therapy is low and acceptable in patients with a first unprovoked proximal deep vein thrombosis (DVT) or pulmonary embolism (PE) who have completed 3 months of therapy and who have a negative D-dimer test on therapy and 1 month after stopping therapy.
| Condition | Intervention |
|---|---|
|
Deep Vein Thrombosis Pulmonary Embolism |
Other: Discontinue anticoagulant therapy (Negative d-dimer) Other: Continue on anticoagulant therapy (positive d-dimer) |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Cohort Study to Test That There is a Low Risk of Recurrent VTE in Patients With a First Episode of Unprovoked VTE Who Stop Anticoagulant Therapy After 3 Months of Treatment in Response to Negative D-dimer Testing |
Resource links provided by NLM:
Further study details as provided by McMaster University:
Primary Outcome Measures:
- Suspected Recurrent DVT [ Time Frame: up to 4 years ] [ Designated as safety issue: Yes ]
- Suspected (recurrent) pulmonary embolism [ Time Frame: up to 4 years ] [ Designated as safety issue: Yes ]
- Bleeding [ Time Frame: up to 4 years ] [ Designated as safety issue: Yes ]
- Death [ Time Frame: up to 4 years ] [ Designated as safety issue: Yes ]
| Enrollment: | 410 |
| Study Start Date: | September 2008 |
| Estimated Study Completion Date: | March 2013 |
| Estimated Primary Completion Date: | March 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: A
Discontinue anticoagulant therapy
|
Other: Discontinue anticoagulant therapy (Negative d-dimer)
Patients with negative d-dimer discontinue long-term anticoagulant therapy.
|
|
B
Continue on anticoagulant therapy
|
Other: Continue on anticoagulant therapy (positive d-dimer)
Patients with positive d-dimer continue or re-start on anticoagulant therapy
|
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Be >= 18 years of age
- Have had ONE episode of unprovoked proximal DVT and/or PE
- Have completed 3 uninterrupted months of warfarin therapy (target INR of 2.0-3.0)
Exclusion Criteria:
- Another indication for long-term anticoagulation (e.g., atrial fibrillation)
A high risk of bleeding as evidenced by any of the following:
- Age greater than 75 years
- Previous episode of major bleeding where the cause was not effectively treated
- Known chronic thrombocytopenia with a platelet count of less than 120,000 x 10^9 /L
- Known chronic renal impairment with a creatinine of more than 150 mumols /litre (1.7 mg/dl)
- Known chronic liver disease with a total bilirubin of more than 25 mumols /litre (1.5 mg/dl)
- Active peptic ulcer disease
- Poor compliance with, or control of, anticoagulant therapy during initial treatment
- Requires dual antiplatelet therapy (e.g. aspirin and clopidogrel)
- A vena caval filter
- Has had D-dimer testing performed within 2 months of potential enrollment other than for evaluation of suspected recurrent VTE that was not confirmed
- Has a life expectancy less than 5 years
- Is unable to attend follow-up visits because of geographic inaccessibility
- Is participating in a competing clinical investigation
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00720915
Locations
| United States, District of Columbia | |
| Lombardi Cancer Center | |
| Washington, District of Columbia, United States, 20057 | |
| United States, Iowa | |
| University of Iowa Hospitals and Clinics | |
| Iowa City, Iowa, United States, 52242 | |
| United States, Massachusetts | |
| Brigham and Women's Hospital | |
| Boston, Massachusetts, United States, 02115 | |
| Beth Israel Deaconess Medical Centre | |
| Boston, Massachusetts, United States, 02215 | |
| United States, Michigan | |
| Henry Ford Hospital | |
| Detroit, Michigan, United States, 48202 | |
| United States, North Carolina | |
| UNC Thrombophilia Program | |
| Chapel Hill, North Carolina, United States, 27599-7035 | |
| United States, Utah | |
| Intermountain Medical Centre | |
| Murray, Utah, United States, 84152 | |
| Canada, Ontario | |
| Henderson Hospital | |
| Hamilton, Ontario, Canada, L8V1C3 | |
| McMaster University | |
| Hamilton, Ontario, Canada, L8N 3Z5 | |
| St. Joseph's Health Care Centre | |
| Hamilton, Ontario, Canada, L8N 4A6 | |
| Hamilton General Hospital | |
| Hamilton, Ontario, Canada, L8L 2X2 | |
| Ireland | |
| Limerick, Mid Western Regional Hospital | |
| Limerick, Ireland | |
| United Kingdom | |
| Addenbrooke's Hospital | |
| Cambridge, United Kingdom, B2 0QQ | |
| Churchill Hospital | |
| Oxford, United Kingdom, OX3 7LJ | |
Sponsors and Collaborators
McMaster University
Canadian Institutes of Health Research (CIHR)
Investigators
| Principal Investigator: | Clive Kearon, MB MRCP(I) FRCP(C) PhD | McMaster University |
More Information
No publications provided
| Responsible Party: | McMaster University |
| ClinicalTrials.gov Identifier: | NCT00720915 History of Changes |
| Other Study ID Numbers: | CTMG-2007-DODS |
| Study First Received: | July 21, 2008 |
| Last Updated: | April 20, 2012 |
| Health Authority: | Canada: Health Canada |
Keywords provided by McMaster University:
|
unprovoked deep vein thrombosis unprovoked pulmonary embolism anticoagulant therapy |
Additional relevant MeSH terms:
|
Embolism Pulmonary Embolism Thrombosis Venous Thrombosis Venous Thromboembolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases Thromboembolism |
Anticoagulants Fibrin fragment D Hematologic Agents Therapeutic Uses Pharmacologic Actions Antifibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Hemostatics Coagulants |
ClinicalTrials.gov processed this record on May 16, 2013